四環醫藥：中期報告2021.pdf

1、2021Interim Report中期報告(incorporated in Bermuda with limited liability)（於百慕達註冊成立的有限公司）Stock Code 股份代號：0460Sihuan Pharmaceutical Holdings Group Ltd.四環醫藥控股集團有限公司Interim Report 2021 中期報告Sihuan Pharmaceutical Holdings Group Ltd.四環醫藥控股集團有限公司公司簡介CORPORATE PROFILEFounded in 2001 and listed on the Main Board

2、 of The Hong Kong Stock Exchange Limited in 2010,Sihuan Pharmaceuticals Holdings Group Ltd.(”Sihuan Pharmaceutical”or the”Company”,together with its subsidiaries the”Group”)(Stock Code:00460.HK)is an international pharmaceutical company led and driven by both innovation and generic,with an independe

3、nt and leading independent research and development(”R&D”)technology platform,a rich global product pipeline and a mature and excellent sales system.Focusing on high-growth therapeutic areas such as oncology,metabolic diseases,medical aesthetics,anti-infectives,digestive system,cardiovascular and ce

4、rebrovascular,Sihuan Pharmaceutical is building a leading medical aesthetics and biopharmaceutical leader in China with a two-wheel drive strategy of independent innovation and research and incubation to cultivate high-growth new businesses.四環醫藥控股集團有限公司（四環醫藥 或本公司，連同其附屬公司為 本集團）（股份代號：00460.HK）創立於二零零一年

5、，二零一零年於香港聯合交易所有限公司主板上市，是一家以創新為引領，堅持創新驅動、仿創並舉，擁有獨立領先的自主生產、研究與開發（研發）技術平台，具備豐富的全球化產品管線和成熟卓越銷售體系的國際化製藥企業。四環醫藥聚焦腫瘤、代謝病、醫美、抗感染、消化系統、心腦血管等高增長治療領域，以自主創新研發和孵化培養高增長新業務的雙輪驅動戰略，打造中國領先的醫美和生物醫藥領軍企業。目錄CONTENTS2 公司資料 Corporate Information5 管理層討論及分析 Management Discussion and Analysis37 其他資料 Other Information56 獨立審閱報

6、告 Independent Review Report58 中期簡明綜合財務狀況表 Interim Condensed Consolidated Statement of Financial Position60 中期簡明綜合損益及其他全面收益表 Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income62 中期簡明綜合權益變動表 Interim Condensed Consolidated Statement of Changes in Equity64 中期簡明綜合現金